|Title:||Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study||Authors:||PO-DA CHEN
|Keywords:||Cholangiocarcinoma; Hepatocellular carcinoma; Liver cancer; Mixed hepatocellular-cholangiocarcinoma||Issue Date:||2021||Publisher:||John Wiley and Sons Inc||Journal Volume:||26||Journal Issue:||10||Start page/Pages:||e1774-e1785||Source:||Oncologist||Abstract:||
Background: Combined hepatocellular-cholangiocarcinoma (HCC-CC) is an aggressive primary liver cancer. However, the clinical features are not clearly understood because of limited literature and the complex nature of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Methods: The records of 100,754 patients with newly diagnosed liver cancer between 2004 and 2013 were obtained from the Taiwan Cancer Registry. The primary outcome measures were overall survival and local recurrence-free survival. The median follow-up time was 60 months (29–120 months). Results: HCC-CC tended to share some characteristics with HCC, including increased frequency of stage I cases, high individual tumor rates, and similar patterns of viral hepatitis B and hepatitis C infections. In contrast, HCC-CC showed malignant behavior similar to that of CC, as high-grade tumor cell differentiation and presentation of jaundice were predominant in HCC-CC and CC compared with HCC. Overall survival and local recurrence-free survival rates of HCC-CC were between HCC and CC rates. The mortality rate of HCC-CC was 79.2% (HCC, 77.5%; CC, 93.5%) and the local recurrence rate of HCC-CC was 65.3% (HCC, 74.6%; CC, 88.4%). Surgical treatment was an independent factor for the long-term prognosis of HCC-CC, whereas transarterial chemoembolization (TAcE) promoted survival in both surgical and nonsurgical groups. Conclusion: Our data confirmed that, although it reflects the malignant behavior of CC, HCC-CC should mainly be characterized as a subtype of HCC. With careful selection of patients, curative resection and TAcE might benefit the survival of patients with HCC-CC. Implications for Practice: Combined hepatocellular-cholangiocarcinoma (HCC-CC) is a rare cancer that shares demographic characteristics, as well as survival probabilities, with both hepatocellular carcinoma and cholangiocarcinoma. It occurs frequently in patients with hepatitis B virus infection, cirrhotic liver background, and early-stage disease. Compared with 20% of initial resection rates of its counterparts, HCC-CC has higher initial resection rate (55%). Although short-term overall survival is inferior to HCC, its long-term overall survival is similar with HCC. ? 2021 AlphaMed Press.
|ISSN:||1083-7159||DOI:||10.1002/onco.13893||SDG/Keyword:||adult; aged; Article; bile duct carcinoma; cancer prognosis; cancer staging; cancer survival; Charlson Comorbidity Index; chemoembolization; Child Pugh score; cohort analysis; comorbidity; disease free survival; disease specific survival; female; follow up; hematopoietic stem cell; hemiplegia; hepatitis B; hepatitis C; histology; human; jaundice; liver cell carcinoma; liver cirrhosis; local recurrence free survival; lymph node dissection; lymph node metastasis; major clinical study; male; mortality rate; outcome assessment; overall survival; recurrence risk; recurrent disease; surgical mortality; survival rate; tumor cell; very elderly; virus infection; bile duct cancer; bile duct carcinoma; chemoembolization; intrahepatic bile duct; liver cell carcinoma; liver tumor; retrospective study; tumor recurrence; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cholangiocarcinoma; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.